Agenus to Present at Windhover's Therapeutic Area Partnerships Conference
November 26, 2012 10:45 ET
|
Agenus Inc.
Agenus' HerpV Named One of the "2012 Top Programs to Watch" by Windhover
LEXINGTON, Mass., Nov. 26, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for...
Efficacy Shown With GlaxoSmithKline's Phase 3 Malaria Vaccine Candidate, Which Contains Agenus' Qs-21 Stimulon(R) ADJUVANT
November 09, 2012 04:00 ET
|
Agenus Inc.
Phase 3 study met its primary endpoint and demonstrates statistically significant protection against clinical and severe malaria in infants
Contains Agenus' QS-21 Stimulon1 adjuvant...
Agenus Reports Third Quarter 2012 Financial Results
October 25, 2012 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Oct. 25, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a biotechnology company working to develop novel immunology based treatments for cancers and infectious diseases, today...
Agenus Commences Phase 2 Study of HerpV Vaccine for the Treatment of Genital Herpes
October 23, 2012 07:00 ET
|
Agenus Inc.
HerpV is the most clinically advanced therapeutic vaccine candidate for the treatment of genital herpes
Contains Agenus' QS-21 Stimulon® adjuvant currently being studied in 17 clinical...
Agenus to Report 3rd Quarter Financial Results on October 25, 2012; Conference Call to Follow
October 18, 2012 09:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Oct. 18, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) will release its third quarter financial results before the market opens on October 25, 2012.
Agenus executives will...
Agenus to Present at 3rd Annual Cancer Immunotherapy Conference
September 28, 2012 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Sept. 28, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of vaccines for cancer and infectious diseases, today announced that the company will be presenting at the...
Agenus to Present at the NewsMakers in the Biotech Industry Conference and the Rodman & Renshaw Global Investment Conference
September 04, 2012 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of vaccines for cancer and infectious diseases, today announced that Garo Armen, Ph.D, chairman and CEO of...
Agenus Announces Publication of Key Data Showing Antitumor Activity of Prophage Vaccine (HSPPC-96) in Clinical Cancer Research
August 08, 2012 10:52 ET
|
Agenus Inc.
LEXINGTON, Mass., Aug. 8, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a biotechnology company working to develop novel immunology-based treatments for cancers and infectious diseases, today...
Agenus Reports Second Quarter 2012 Financial Results
August 02, 2012 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Aug. 2, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a biotechnology company working to develop novel immunology-based treatments for cancers and infectious diseases, today...
Agenus to Report 2nd Quarter Financial Results on August 2, 2012; Conference Call to Follow
July 26, 2012 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., July 26, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) will release its second quarter financial results before the market opens on August 2, 2012.
Agenus executives will host...